PharmaCielo Ltd. (PCLOF) reports developments as a Canada-headquartered cannabis products company whose wholly owned subsidiary, PharmaCielo Colombia Holdings S.A.S., cultivates and processes medical cannabis flower and cannabis extracts in Rionegro, Colombia. Its updates center on dried flower and medicinal-grade extract production for natural pharmaceutical and consumer-products channels, international customer and export activity, revenue trends, gross margin, adjusted EBITDA, and cost controls.
Company news also covers capital-structure actions, including secured debentures, warrants, shares issued for interest or debt settlement, TSX Venture Exchange approvals, annual meeting matters, and corporate reporting status affecting trading of its shares.
Summary not available.
Summary not available.
Summary not available.
PharmaCielo has achieved GMP certification from INVIMA for its Phytotherapeutics, confirming the quality of its cannabis extracts and proprietary cultivars. This certification enhances PharmaCielo's reputation as a leading producer in Colombia, with its Rionegro facility being one of the largest globally, processing 360 tonnes of biomass annually. The company aims to receive EU-GMP certification in H1-2022, having already complied with its standards since early 2021. Additionally, PharmaCielo has granted 1,375,000 Restricted Share Units and 550,000 stock options to directors and employees.